morning, and everyone, joining. Good for thanks you, Thank Susan.
strong all XXXX a pleased continued with are across business. report to areas We the start to of very momentum
few and a growth trends we with ml XX of begin vials. with top sales for very XX% me highlights. encouraging growth XX line the EXPAREL Today, Let ml both reported
We shift both are believe ambulatory the and utilize blocks board nerve by in hospitals are the community driven increased which ongoing the tissue ultrasound-guided procedures, settings. soft the regional approaches we anesthesiology field toward that penetration and in in seeing across
joint On procedures. and opioid-sparing and and the spine, a procedural cuff, the foundation solutions broad front, reconstruction building utilization orthopedics fracture hip of we're awareness of EXPAREL for rotator
procedures with tissue we infiltration. are average blocks XXX each record finally, base nerve customer brachial a by new driven I'm an coming and and a QX continues global orthopedic happy leading from officially procedural Our month. health our pain achieve at completed growth block in soft is osteoarthritis expanded field non-opioid Pacira XX a being now strong three growth further customers TKA This With trajectory, of pain. growth on a solution regenerative and in we non-opioid management firmly surgery, to our multimodal with acquisition this nerve that of oral is MyoScience, growth ml expand, transaction in are CryoTech. for plexus To provider EXPAREL positioned become ordering report which XX leadership goal, with And for periarticular advancing of we customers active use pillars. pain to Pacira management ml is to now high X,XXX solidifies accounts over well in peripheral and solutions.
to directly and First, the of continued in innovative rapidly and new complement leveraging strategy I'll key expansion candidates; third, first our along partnerships clinical of with EXPAREL settings; platform our the our our commercial pillar, with audience align start surgical use that acquisitions EXPAREL pain second, pursuing infrastructure and expanding EXPAREL. DepoFoam advance and continuum. the position
pleased seeing on very million, represent which -- to XX%. sales than net are remain of with between EXPAREL of more trends, we deliver the and we would and year-over-year are robust We are million that growth $XXX track and $XXX growth
As we be key EXPAREL, look focusing three a drivers. growth I'll on take at closer
or After of protocols, academic pain management influential rollout the First, centers. opioid-sparing continued from Recovery teaching Surgery, EXPAREL-based Enhanced ERAS
solidified anesthesiologists and third, from the as pecs great EXPAREL of nerve success to in plexus brachial engagement pain then foundation who of level are multimodal and block blocks orthopedic trends, blocks high field the Second, management. TAP as go-to as It EXPAREL And the of traction successfully reporting is such of surgeries. extending with strong orthopedic the significant solution for fundamental as -- being a our procedural to partnership becoming J&J, clear a the EXPAREL role due regarding part ERAS partner protocols. of choice recognized with that space which has is Pacira various
plane evident by using for radical CTCA's as ASURE and epidurals using as advanced debulking postsurgical intra-abdominal length they're regimen narcotic use for a the in patient-controlled is XX% transverse pain. of as The for the use in And of protocols narcotic Procedure, ovarian an CTCA in March XX.X a America real in analgesia, open cancers, featured overall. from X.X days. managing on abdominis Whipple well as Oncology foundation multimodal consumption average evidenced-based reduction positive surgeries. decrease in Centers is three. blocks example taking recovery. opioid ASURE, stay excellent commonly the EXPAREL seeing than of XX% Under program, Treatment success This progress XX% issue is on relying day known data. the field duodenectomy cancer major studies procedures surgical the rather Our of of which Times in place. results collaboration a a complications with world CTCA stands was increase of Cancer or The from to ASURE is total the for showing and surgical XX% pancreatic And decrease postsurgical accompanied ASURE a
We've with drop collaboration our achieving too, and considerable the significant also average to Specialists, stay, Here days in X.X from a MEDNAX nurses. of is Maternal-Fetal anesthesiologists, days. progress obstetricians in CTCA which perioperative of made X.X decreased team length
United Here, management C-sections we're pain to a each platform pain month cesarean There block aiming -- abdominis EXPAREL section as featuring management time with performed their for babies. new are mother's and approximately allow innovative States. in more recover to ability implement targeted for to spend the the transverse an XXX,XXX faster long-lasting opioid-free
regimen to launching touch the multiple intend educational around for for women's there's student recovery the opioids. broad Anesthetists significant is protocols we of American of enhanced and are XX,XXX anesthetists real-world represents professional in negative platform to across Nurse health. So here nurse with This more of goal The ERAS non-opioid Association platform be empower that to a nurse pain We than for support registered effects educational clearly ERAS on establishing an the eliminate AANA. is anesthetists. key voice side strategies. item AANA in to help or need partnership final a The a nurse to association components
to interest anesthesiology and we engagement EXPAREL for upper a seeing block go the turn from procedures extremity as well. exceedingly nerve the driver, brachial plexus receptivity growing Now The let to growth continues to me market our are second community.
painful undergoing becoming practice XX institutional a their as these as only available the brachial dose As habits well anesthesiologist are EXPAREL patients procedures, single long-acting of mainstay protocols. blocks for ml block plexus nerve
an study was been accepted Phase the the importantly, service stay, a Our of case. block the paving shifting Pain thought for per in in ERAS EXPAREL this to III recently demonstrated setting. was peer-reviewed and highly statistically Phase transition cesarean block Obstetric opioid-sparing would These also superiority of advantages publication result significant practice top significant IV with block savings General the EXPAREL that nerve versus are physicians as recognize of an a year, procedures EXPAREL TAP growth way plexus as patients site XX% accelerate the brachial accepted ambulatory to the growth surgery opioids emphasize, of we payers TAP Anesthesia every In use important reduction -- study, centers. podium of by study Medicine. inpatient care, significant undergoing as of protocols EXPAREL reduced control taking in SOAP, to surgery placebo that we XX% centers. of and When in reductions achieving are setting Meeting this for this awareness year-over-year TAP benefits a EXPAREL ambulatory Perhaps, with opioids. the pain and high statistically opioid-free. we typically ambulatory to in value the is with scores Notably, in look rates or know cited prefer improved blocks patients pain procedures field of emerging Earlier economic ambulatory at oral in and achieves this block growth for sections. most bupivacaine We cesarean through XX-hour seeing XX% regional pain opioids, hours. reported EXPAREL the strong results transition demonstrated block. for the with Society from driver, patients weekend. of to a and Annual P expect our have while XX an most and EXPAREL data line and we Perinatology To significant nerve were as presentation surgery place are as which around grows sections at setting for the control prefer to
growth hold. see On -- continue the take drivers to reimbursement front, we drivers
is CMS CXXXX and oral well oral to at procedures. sustained under surgery Association overcome for per the drug options non-opioid product-specific team $X.XX milligram. American ambulatory introducing basis. as Both release code working for upfront surgery critical reimbursement Likewise, ASC a in by payer-by-payer X, our and codes hurdles is January the billing centers EXPAREL Dental know, payers new therapeutic the reimbursement with administrative closely a facilitate reimbursing on you to As code on used commercial need of as in effect has now took recognized the infiltration
has this Aetna and into meaningfully with program program national Our a ASC pilot are now results, initiative. we expanding delivered
a support undergoing has the non-opioid decreasing stated -- teens for need Aetna ASCs EXPAREL objective option the in use goal, carve are rolling demand of young for recall, community, strong country. this out opioid may across they extraction. the corporate of the In tooth for EXPAREL been out of agreements an has dental wisdom for the very you and opioids As underscoring adults and
around use practices early leading front The moving accelerate We environment. where on is through less patients. still fracture EXPAREL are continue final the we expanded shoulder, joint EXPAREL year expensive evolve ambulatory favorable as of EXPAREL discuss in are the reconstruction. this indicators to it's driving believe to to hip spine, payer reimbursement item new and days, the seeing highly will orthopedics the While patients and
their These EXPAREL EXPAREL thousands provided broad practitioners. programs. significant Here, world-class visibility of partnership have reach through our J&J driven care and health update educational has commercial to
the would control than or applications. to two and and growth, innovative assets our moments. a third these development, opportunity brings selected acute, leveraging that our delivery for DepoFoam and products align pain flexibility be care. provide our the of typically the of area Rich opioids to other in bupivacaine a subacute Depo in pillar specifics additional with clinical chronic pillar, where medical dexmedetomidine. us complementary programs share of as for EXPAREL. standard provide the second intrathecal technologies platform growth now -- an subarachnoid and Both pain and to strategy of few safety local will of anesthetic Turning This DepoFoam-based DepoFoam customizability pillar We are to need pursuing proven
of strength This our MyoScience highly site device to cryoanalgesia EXPAREL and to like therapy in ioveraº of system I offering. a strategies. from Ioveraº alleviate brain our infrastructure, domain will pain greatly the injury opioid-sparing of surgery. benefit network signals established expertise transmitted pain financial by deep or being in from to Pacira and disrupting known handheld growing adds to a benefits to pain completed and We the acquisition CryoTech. deliver non-opioid Here, believe would the transaction partnership now specifically, via commercial as to complementary our the ioveraº recently as is highlight
Now procedural care by perfect that the transaction officially is that leadership underway. integration is is offering Ioveraº well further providers solution for only solidifies health multimodal closed, EXPAREL the fit position a TKA for procedures. strategic our
Importantly, to us the a market pending affording there protection leader clinical, XX barrier over issued in and as establish is high entry of with in efforts into patents to patents offering commercial ioveraº and XXXXs XX the educational a ability invest the fully cryoanalgesia.
two will patient Our on initial focus strategy opportunities. go-to-market care broad
EXPAREL and before, for and after management ioveraº surgery. non-opioid First, during pain
any for to EXPAREL prescription allow As opioid-free, weight control with with end goal of prepare many setting, osteoarthritis replacements. surgical for activities, months plus pain several an prehabilitation daily to provide have and existing pain postsurgical cessation. EXPAREL code to opinion hip are reimbursement smoking with XX% is our leaders we especially using use surgery patients physical normal patients for With an and them of or pain control for knee and therapy post EXPAREL opioid-free control achieve and CPT ioveraº, results loss along near to sleep. to rapid opioids. of using this ioveraº changes ioveraº stage presurgical In like return -- to as XXXXX non-opioid key other spine and pathway knee, environment provide total
training with the network with of for signed delivery goal EXPAREL begin opioid-free next plus a In agreement use ioveraº, an fact, major a integrated to have of weeks. with couple of in surgery we
golf, would pain osteoarthritis vacations to or grandchildren several surgery-free tennis, market opioid-free, months walking for as patients second drug-free, such simply for be surgery family seeking delay the for who or as well patients an hiking as weddings. events, with course The as desire over such active of management lifestyle,
is clinical age typically focus a of OA. and who the the data XX there from intervention initial osteoarthritis Surgical success ioveraº individuals are be treatment. patients have the osteoarthritis knee, X suffering under where with for symptomatic XX. of body will million of is nearly the Our There growing last knee million United in States knee demonstrating resort
standpoint, of the advanced the positioned day, meaningful When who technologies the in with concept nerve optimal an competitive we this in believe body's very centers of experience and that at pathway ambulatory we patients We In procedures. market cash the pay response several blocks, market, for market. cold. regarding -- treat are or care billion well non-opioid per advantage is use planned avoid the to look continue the where patients following a have osteoarthritis all we to natural technology potential delay events. both for can From offices an $X enjoy of other to technology physician a dialogue ioveraº where options believe insured ioveraº ioveraº across for extender seek trained ioveraº to extensive currently managing share summary, to KOLs surgery or hour and can ioveraº takes active PRP physician and on based capture plan pain as where the lifestyle is
a a tip. revenue treatment the in a technology fluoroscopy last can effect the It handheld opportunity allowing repeat is procedure-specific or tissue their immediate risk in device practices -- not pain an relief is is treatment does single or smart as treatment. that safe to for new most medical convenient surrounding the ioveraº Importantly, with practice settings, There ultrasound delivered landmark, months to damage use over the anatomic regenerates by as incorporate that generator. nerve time. single as several to guidance Therapy
closed, out our -- expanding developing rolling and additional we're manufacturing commercial clinical plans, is actively evidence. commercial Now capacity acquisition include that which the expanding
provide bundle centers overview, like Richard the call turn activities. and HOPD, Dr. color now access we regulatory of that As with work would offices clinical Rich? the Scranton with for on care. to to I will physician payers commercial additional EXPAREL, to government and some -- and With to outside over ambulatory site provide our ioveraº to regulated of
